You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Prevention of corneal transplant rejection using AAV-HLA-G combination therapy

    SBC: Bedrock Therapeutics, Inc.            Topic: NEI

    Contact PD/PI: GILGER, BRIAN C Abstract Corneal blindness is a leading cause of global blindness, with allogeneic corneal transplantation (CT) being the most common form of tissue transplantation worldwide. Though approximately 180,000 CT surgeries are carried out each year, around 12.7 million are currently awaiting a donor cornea to undergo the operation. Still, CT surgery is accompanied by a hi ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. A Phase 3 Multicenter, Randomized, Vehicle-Controlled Clinical Study to Evaluate the Safety and Efficacy of an Ophthalmic Emulsion of Nintedanib in Pterygium Patients

    SBC: CLOUDBREAK THERAPEUTICS LLC            Topic: NEI

    Pterygium is a common ocular surface disease with abnormal fibrovascular growth on the cornea that affects about 10 million individuals in the US. Later-stage disease impairs vision and early to middle stage disease causes worry and anxiety about eye appearance in patients. The current standard of care is surgical removal of lesion tissue. However, rapidly growing lesions recur in about 10% of pat ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Healthy Aging: an EEG-based wearable device to accurately monitor sleep and enhance quality for improved cognitive functioning

    SBC: DEEPWAVE TECHNOLOGIES INC            Topic: NIA

    PROJECT SUMMARY More than 40% of individuals as young as 60 start to experience some sort of cognitive decline. Among these, nearly one person in five develops mild cognitive impairment (MCI), a potential precursor of severe neurodegenerative diseases, like Alzheimer’s Disease (AD) and dementia. Today, AD and dementia represent an economic burden of $277 B/year in the U.S. alone. Nothing can be ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. ANTIMICROBIAL TECHNOLOGY TO ACTIVELY MITIGATE HYDROCEPHALUS SHUNT INFECTIONS LONG TERM

    SBC: Thrombodyne Inc            Topic: 999

    ABSTRACTShunts placed in patients to manage cerebrospinal fluid (CSF) drainage are indispensable in medical practice, however, they are susceptible to infection caused by local microflora leading to high mortality and morbidity. Shunts are generally made of carbon or silicone rich polymers to maintain desirable properties such as flexibility, but these inert polymers offer an attractive refuge for ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Hyperphosphorylated tau aggregation kit to identify tauopathy risk factor

    SBC: CAYMAN CHEMICAL COMPANY, INCORPORATED            Topic: NIA

    PROJECT SUMMARY Tauopathies are a group of neurodegenerative disorders sharing the common pathology of the tau protein in the central nervous system. The most prominent tauopathy is Alzheimer’s disease (AD) that affects nearly 6 million Americans and more than 30 million people worldwide. Additional tauopathies include frontotemporal lobar degeneration with tau, Pick’s disease, progressive sup ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  6. A youth-specific helmet for preventing traumatic brain injury

    SBC: SAVIOR BRAIN INC.            Topic: NINDS

    PROJECT SUMMARY Head injuries, including nearly 4 million concussions per year, are common among the nearly 40 million participants in organized youth sports in the United States. Despite recent technologies marketed to reduce concussion risk, head injuries continue to rise among youth athletes. Furthermore, studies to improve protective equipment have largely focused on adult populations, leading ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Developing Drug-like Small Molecules that Target Toxic Repeat RNAs to Alleviate Myotonic Dystrophy Type 1-derived Mis-Splicing

    SBC: Nymirum, Inc.            Topic: 104

    Project Summary Abstract Nymirum will utilize its technology platform to identify and optimize a drug-like, orally available small molecule that binds toxic CUG repeat RNAs to rescue myotonic dystrophy type 1 (DM1) derived mis-splicing and treat the disease. DM1 is a rare genetic disorder that leads to progressive muscle degeneration, cardiovascular disease, severe cognitive disabilities, insulin ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Photo-mediated ultrasound therapy for treatment of cutaneous vascular malformations

    SBC: PHOTOSONOX LLC            Topic: NIBIB

    ABSTRACT: Cutaneous vascular malformations (CVM), such as port wine stain (PWS) which occurs in 0.3–0.5% of newborns, are often a cause of great concern to patients for both medical and cosmetic reasons. Laser irradiation with flashlamp-pumped pulsed dye lasers, i.e. photothermolysis therapy (PTT), is currently the gold standard treatment for PWS. Most patients with PWS, however, fail to clear c ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Selective actin remodeling of sensory neurons for acute pain management

    SBC: Neurocarrus Inc.            Topic: NINDS

    PROJECT SUMMARY There is an urgent need for new approaches to treat acute human pain without the risk of Substance Use Disorders (SUDs). The most effective approved pain pharmaceuticals, including narcotics and anesthetics, are not neuron-specific and consequently suffer from off-target effects like addiction, inhibition of motor neurons, and destruction of the surrounding tissues. When inflammati ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Rapid and non-invasive device for drug detection through sweat

    SBC: ARBORSENSE INC            Topic: NIDA

    Project Summary In the NIDA SBIR Phase I project, Arborsense will develop a portable sweat-based screening device for rapid, non-invasive, point-of-need, and quantitative detection of drugs of abuse. The use and abuse of potentially- addictive substances has become a national crisis with immense social (~93,000 deaths in 2020) and economic costs (~$400B annually). Consequently, regular drug-use te ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government